Monopar Therapeutics Stock Price, News & Analysis (NASDAQ:MNPR) $0.30 +0.01 (+3.39%) (As of 11/29/2023 ET) Add Compare Share Share Today's Range$0.29▼$0.3350-Day Range$0.29▼$0.6052-Week Range$0.27▼$3.82Volume155,473 shsAverage Volume2.96 million shsMarket Capitalization$4.53 millionP/E RatioN/ADividend YieldN/APrice Target$13.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Monopar Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside4,167.9% Upside$13.00 Price TargetShort InterestHealthy3.14% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.43Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.67) to ($0.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.06 out of 5 stars 3.4 Analyst's Opinion Consensus RatingMonopar Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.00, Monopar Therapeutics has a forecasted upside of 4,167.9% from its current price of $0.30.Amount of Analyst CoverageMonopar Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.14% of the float of Monopar Therapeutics has been sold short.Short Interest Ratio / Days to CoverMonopar Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Monopar Therapeutics has recently increased by 277.87%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMonopar Therapeutics does not currently pay a dividend.Dividend GrowthMonopar Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MNPR. Previous Next 2.5 News and Social Media Coverage News SentimentMonopar Therapeutics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Monopar Therapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for MNPR on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Monopar Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders41.60% of the stock of Monopar Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 6.18% of the stock of Monopar Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Monopar Therapeutics are expected to decrease in the coming year, from ($0.67) to ($0.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Monopar Therapeutics is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Monopar Therapeutics is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMonopar Therapeutics has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Monopar Therapeutics Stock (NASDAQ:MNPR)Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Read More MNPR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MNPR Stock News HeadlinesNovember 9, 2023 | finance.yahoo.comMonopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent DevelopmentsNovember 9, 2023 | finance.yahoo.comMonopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent DevelopmentsNovember 30, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 9, 2023 | finance.yahoo.comMonopar Therapeutics Inc Reports Q3 2023 Financial Results and Progress in Clinical ProgramsNovember 3, 2023 | markets.businessinsider.comPromising Early Efficacy Results and Diverse Drug Development Portfolio Drive ‘Buy’ Rating for Monopar Therapeutics IncNovember 1, 2023 | finance.yahoo.comMonopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual MeetingOctober 10, 2023 | finance.yahoo.comMonopar to Participate in the Roth MKM 2023 Healthcare Opportunities ConferenceSeptember 5, 2023 | finance.yahoo.comMonopar to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceNovember 30, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comSeptember 5, 2023 | finance.yahoo.comMonopar to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 10, 2023 | finance.yahoo.comMonopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent DevelopmentsAugust 8, 2023 | finance.yahoo.comMonopar Provides Encouraging Camsirubicin Clinical Data UpdateAugust 8, 2023 | finance.yahoo.comMonopar Provides Encouraging Camsirubicin Clinical Data UpdateJuly 11, 2023 | finance.yahoo.comMonopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of SingaporeJuly 11, 2023 | finance.yahoo.comMonopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of SingaporeJune 21, 2023 | finance.yahoo.comMonopar to Participate in the Radiopharma Forum by the Lake 2023June 14, 2023 | finance.yahoo.comMonopar to Participate in the Maxim Group’s Healthcare Virtual ConferenceJune 1, 2023 | msn.comHC Wainwright & Co. Reiterates Monopar Therapeutics (MNPR) Buy RecommendationJune 1, 2023 | finance.yahoo.comMonopar Announces Encouraging Camsirubicin Phase 1b Trial UpdateJune 1, 2023 | finance.yahoo.comMonopar Announces Encouraging Camsirubicin Phase 1b Trial UpdateMay 29, 2023 | finance.yahoo.comMonopar Therapeutics Inc. (MNPR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?May 15, 2023 | markets.businessinsider.comExpert Ratings for Monopar TherapeuticsMay 15, 2023 | msn.comHC Wainwright & Co. Maintains Monopar Therapeutics (MNPR) Buy RecommendationMay 15, 2023 | markets.businessinsider.comMonopar Therapeutics Inc (MNPR) Gets a Buy from H.C. WainwrightMay 13, 2023 | investing.comMonopar Therapeutics (MNPR) Earnings Dates & ReportsMay 11, 2023 | marketwatch.com10-Q: MONOPAR THERAPEUTICSMay 11, 2023 | finance.yahoo.comMonopar Therapeutics Reports First Quarter 2023 Financial Results and Recent DevelopmentsSee More Headlines Receive MNPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Monopar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today11/30/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MNPR CUSIPN/A CIK1645469 Webwww.monopartx.com Phone847-388-0349FaxN/AEmployees11Year Founded2014Price Target and Rating Average Stock Price Target$13.00 High Stock Price Target$24.00 Low Stock Price Target$2.00 Potential Upside/Downside+4,167.9%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,520,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-113.36% Return on Assets-86.28% Debt Debt-to-Equity RatioN/A Current Ratio4.32 Quick Ratio4.32 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.44 per share Price / Book0.69Miscellaneous Outstanding Shares14,870,000Free Float8,682,000Market Cap$4.53 million OptionableNot Optionable Beta0.95 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Chandler D. Robinson M.B.A. (Age 39)M.D., M.Sc., MBA, MSc, Co-Founder, CEO, President & Director Comp: $708.12kMs. Kim R. Tsuchimoto CPA (Age 60)CFO, Secretary, Treasurer & Director Comp: $350.55kMr. Andrew J. Cittadine M.B.A. (Age 51)Chief Operating Officer Comp: $390.41kDr. Patrice P. Rioux M.D. (Age 72)Ph.D., Acting Chief Medical Officer Key CompetitorsRevelation BiosciencesNASDAQ:REVBExicureNASDAQ:XCURBlue Water BiotechNASDAQ:BWVLucy Scientific DiscoveryNASDAQ:LSDISoligenixNASDAQ:SNGXView All CompetitorsInstitutional OwnershipWindsor Advisory Group LLCBought 89,974 shares on 10/31/2023Ownership: 0.635%View All Institutional Transactions MNPR Stock Analysis - Frequently Asked Questions Should I buy or sell Monopar Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Monopar Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MNPR shares. View MNPR analyst ratings or view top-rated stocks. What is Monopar Therapeutics' stock price target for 2024? 4 equities research analysts have issued twelve-month price objectives for Monopar Therapeutics' stock. Their MNPR share price targets range from $2.00 to $24.00. On average, they predict the company's share price to reach $13.00 in the next year. This suggests a possible upside of 4,167.9% from the stock's current price. View analysts price targets for MNPR or view top-rated stocks among Wall Street analysts. How have MNPR shares performed in 2023? Monopar Therapeutics' stock was trading at $2.37 on January 1st, 2023. Since then, MNPR shares have decreased by 87.1% and is now trading at $0.3046. View the best growth stocks for 2023 here. Are investors shorting Monopar Therapeutics? Monopar Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 187,800 shares, an increase of 277.9% from the October 31st total of 49,700 shares. Based on an average trading volume of 923,400 shares, the short-interest ratio is presently 0.2 days. Approximately 3.1% of the shares of the stock are sold short. View Monopar Therapeutics' Short Interest. When is Monopar Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our MNPR earnings forecast. How were Monopar Therapeutics' earnings last quarter? Monopar Therapeutics Inc. (NASDAQ:MNPR) posted its quarterly earnings results on Friday, November, 12th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.22) by $0.02. What other stocks do shareholders of Monopar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Monopar Therapeutics investors own include Entasis Therapeutics (ETTX), Fulcrum Therapeutics (FULC), Sorrento Therapeutics (SRNE), Akero Therapeutics (AKRO), Chimerix (CMRX), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD) and Aquestive Therapeutics (AQST). When did Monopar Therapeutics IPO? (MNPR) raised $9 million in an initial public offering on Thursday, December 19th 2019. The company issued 1,100,000 shares at $8.00 per share. JonesTrading served as the underwriter for the IPO and Arcadia Securities was co-manager. Who are Monopar Therapeutics' major shareholders? Monopar Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Windsor Advisory Group LLC (0.64%). Insiders that own company stock include Andrew Cittadine and Tactic Pharma Llc. View institutional ownership trends. How do I buy shares of Monopar Therapeutics? Shares of MNPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. Does Monopar Therapeutics have any subsidiaries? The following companies are subsidiares of Monopar Therapeutics: Monopar Therapeutics Pty Ltd, and Monopar Therapeutics SARL.Read More This page (NASDAQ:MNPR) was last updated on 11/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.